Merck & Co., Inc. · NYSE (us_market)
Healthcare · Drug Manufacturers - General · United States
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-21$93.11 RISE2025-07-31$78.12 PEAK2025-10-01$90.13 194d | -16.1% 132d | 2025-04-11 $79.18 | 2025-10-01 $90.13 | 83Quality on Sale | 67Deep Value | +15.4% 62d | +13.8% Held 173d |
DROP2025-01-07$101.02 RISE2025-05-14$73.47 PEAK2025-07-25$84.71 199d | -27.3% 127d | 2025-02-27 $90.58 | 2025-07-25 $84.71 | 77Deep Value | 79Quality on Sale | +15.3% 72d | -6.5% Held 148d |
DROP2021-11-04$90.54 RISE2022-02-24$73.51 PEAK2022-05-20$93.55 197d | -18.8% 112d | Missed | Missed | — | — | +27.3% 85d | Missed |
DROP2020-01-02$87.82 RISE2020-03-23$63.36 PEAK2020-04-27$80.13 116d | -27.9% 81d | Missed | Missed | — | — | +26.5% 35d | Missed |
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.
In May 2026, Exelixis announced extensive upcoming presentations at the ASCO Annual Meeting, highlighting new CABOMETYX data and pivotal zanzalintinib trials across multiple hard-to-treat cancers. These data, alongside a new Merck collaboration on the STELLAR-316 phase 3 colorectal cancer trial using MRD-guided enrollment, underscore Exelixis’ push to extend its oncology footprint beyond CABOMETYX. We’ll now assess how this expanded zanzalintinib program, especially the STELLAR-303 and...
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
In addition to developing the vaccine for measles, mumps and rubella, Hilleman's pioneering breakthroughs include hepatitis A and B.
The United States market has shown robust performance with a 2.5% increase over the last week and a remarkable 26% rise in the past year, while earnings are projected to grow by 17% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can offer compelling opportunities for investors seeking to capitalize on potential growth at attractive prices.
ABBV's oncology revenues dip 3% in Q1 as Imbruvica sales slide, though Venclexta, Elahere and Epkinly post solid gains.
On May 26, 2026, Micron’s surge helped propel the S&P 500 and Nasdaq to fresh records even as the Dow lagged.
On May 26, 2026, Micron’s surge helped propel the S&P 500 and Nasdaq to fresh records even as the Dow lagged.
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Tuesday.
RAHWAY, N.J., May 26, 2026--Merck Announces Third-Quarter 2026 Dividend
Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Tuesday.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
AGEN advances BOT/BAL into phase III for MSS colorectal cancer as survival data and global access efforts shape its next growth phase.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| MRK | +5.85% | -2.22% | +12.79% | +54.50% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +2.88% | +3.50% | +16.23% | +41.81% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 119.33M | $14.45B | 0.50% | Trimmed-0.6% | 2026-03-31 |
| Wellington | fundamental | 84.31M | $10.14B | 1.89% | Trimmed-2.5% | 2026-03-31 |
| FidelityFMR | fundamental | 44.52M | $5.35B | 0.28% | Added+9.0% | 2026-03-31 |
| DEShaw | quant | 3.40M | $408.70M | 0.25% | Trimmed-3.4% | 2026-03-31 |
| CapResearch | fundamental | 2.06M | $247.99M | 0.04% | Trimmed-2.4% | 2026-03-31 |
| Citadel | multi-strat | 921.1K | $110.80M | 0.14% | Trimmed-31.2% | 2026-03-31 |
| TwoSigma | quant | 64.3K | $7.74M | 0.01% | Trimmed-14.0% | 2026-03-31 |
| TRowePrice | fundamental | 23.04M | $2.77M | 0.32% | Added+22.9% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | Guindo Chirfi | EVP, Access, Policy & Comms | A Grant / award(deriv) | 19,402 | — | +$0 |
| 2026-05-07 | Guindo Chirfi | EVP, Access, Policy & Comms | A Grant / award(deriv) | 6,628 | — | +$0 |
| 2026-05-07 | Smart Dalton E. III | SVP Fin. - Global Controller | A Grant / award(deriv) | 5,045 | — | +$0 |
| 2026-05-07 | Smart Dalton E. III | SVP Fin. - Global Controller | A Grant / award(deriv) | 2,298 | — | +$0 |
| 2026-05-07 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | A Grant / award(deriv) | 31,044 | — | +$0 |
| 2026-05-07 | Oosthuizen Johannes Jacobus | EVP, Oncology & Int?l | A Grant / award(deriv) | 10,605 | — | +$0 |
| 2026-05-07 | Maraldo David R. | EVP & Pres. MMD | A Grant / award(deriv) | 21,731 | — | +$0 |
| 2026-05-07 | Maraldo David R. | EVP & Pres. MMD | A Grant / award(deriv) | 7,424 | — | +$0 |
| 2026-05-07 | Foard Brian | EVP, Specialty, Pharma, & ID | A Grant / award(deriv) | 31,044 | — | +$0 |
| 2026-05-07 | Foard Brian | EVP, Specialty, Pharma, & ID | A Grant / award(deriv) | 35,351 | — | +$0 |
| 2026-05-07 | Foard Brian | EVP, Specialty, Pharma, & ID | A Grant / award(deriv) | 10,605 | — | +$0 |
| 2026-05-07 | Davis Robert M | Chairman, CEO & President | A Grant / award(deriv) | 139,697 | — | +$0 |
| 2026-05-07 | Davis Robert M | Chairman, CEO & President | A Grant / award(deriv) | 47,724 | — | +$0 |
| 2026-05-07 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | A Grant / award(deriv) | 34,924 | — | +$0 |
| 2026-05-07 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | A Grant / award(deriv) | 11,931 | — | +$0 |
| 2026-05-07 | Larson Betty D | EVP, Chief HR Officer | A Grant / award(deriv) | 23,283 | — | +$0 |
| 2026-05-07 | Larson Betty D | EVP, Chief HR Officer | A Grant / award(deriv) | 7,954 | — | +$0 |
| 2026-05-07 | Li Dean Y | Executive VP & President, MRL | A Grant / award(deriv) | 58,207 | — | +$0 |
| 2026-05-07 | Li Dean Y | Executive VP & President, MRL | A Grant / award(deriv) | 19,885 | — | +$0 |
| 2026-05-07 | Litchfield Caroline | EVP & CFO | A Grant / award(deriv) | 46,566 | — | +$0 |
| 2026-05-07 | Litchfield Caroline | EVP & CFO | A Grant / award(deriv) | 15,908 | — | +$0 |
| 2026-05-07 | Williams David Michael | EVP,Chief Info&Digital Officer | A Grant / award(deriv) | 13,582 | — | +$0 |
| 2026-05-07 | Williams David Michael | EVP,Chief Info&Digital Officer | A Grant / award(deriv) | 4,640 | — | +$0 |
| 2026-05-07 | Zachary Jennifer | EVP, General Counsel | A Grant / award(deriv) | 35,312 | — | +$0 |
| 2026-05-07 | Zachary Jennifer | EVP, General Counsel | A Grant / award(deriv) | 12,064 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | -0.15 | — | — |
| 2026-04-30 | -1.47 | -1.28 | +13.15% |
| 2026-02-03 | 2.01 | 2.04 | +1.47% |
| 2025-10-30 | 2.35 | 2.58 | +9.85% |
| 2025-07-29 | 2.03 | 2.13 | +5.04% |
| 2025-04-24 | 2.14 | 2.22 | +3.98% |
| 2025-02-04 | 1.67 | 1.72 | +3.30% |
| 2024-10-31 | 1.57 | 1.57 | +0.03% |
| 2024-07-30 | 2.14 | 2.28 | +6.31% |
| 2024-04-25 | 1.92 | 2.07 | +7.74% |
| 2024-02-01 | -0.11 | 0.03 | +127.48% |
| 2023-10-26 | 1.95 | 2.13 | +9.51% |
| 2023-08-01 | -2.18 | -2.06 | +5.41% |
| 2023-04-27 | 1.34 | 1.40 | +4.76% |
| 2023-02-02 | 1.54 | 1.62 | +5.36% |
| 2022-10-27 | 1.71 | 1.85 | +8.28% |